MedPath
Found 111 clinical trials|View Analysis
Sort by:

Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome

Phase 4
Not yet recruiting
Conditions
Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Biological: Biological tests
Diagnostic Test: MRI
Diagnostic Test: Neuropsychological tests
First Posted Date
2024-11-26
Last Posted Date
2024-11-26
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Target Recruit Count
60
Registration Number
NCT06706102
Locations
🇫🇷

CHU de Saint-Etienne, Saint-Étienne, France

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

Not Applicable
Recruiting
Conditions
Hematologic Malignancy
Solid Tumor
Sickle Cell Disease
Aplastic Anemia
Immune Deficiency
Metabolic Disorder
First Posted Date
2024-11-14
Last Posted Date
2024-11-28
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
60
Registration Number
NCT06689800
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies

Phase 1
Recruiting
Conditions
Hematologic Malignancies
Adult
Interventions
Drug: KQB198
Drug: Dasatinib
First Posted Date
2024-10-17
Last Posted Date
2024-12-05
Lead Sponsor
Kumquat Biosciences Inc.
Target Recruit Count
122
Registration Number
NCT06645886
Locations
🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

Oncology Hematology Cincinnati, Cincinnati, Ohio, United States

🇺🇸

Texas Oncology Austin Central, Austin, Texas, United States

and more 4 locations

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 3
Recruiting
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
First Posted Date
2024-07-18
Last Posted Date
2025-01-07
Lead Sponsor
Genmab
Target Recruit Count
360
Registration Number
NCT06508658
Locations
🇺🇸

Valkyrie Clinical Trials /ID# 269935, Los Angeles, California, United States

🇺🇸

Northwest Cancer Center - Dyer Clinic /ID# 269787, Dyer, Indiana, United States

🇺🇸

Community Cancer Trials Of Utah /ID# 271715, Ogden, Utah, United States

and more 85 locations

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Phase 1
Recruiting
Conditions
Recurrent Oligodendroglioma
Progressive Oligodendroglioma
Interventions
Biological: TTRNA-DC vaccines with GM-CSF
Biological: Autologous Hematopoietic Stem cells (HSCs)
Biological: TTRNA-xALT
Drug: Td vaccine
First Posted Date
2024-02-12
Last Posted Date
2024-11-19
Lead Sponsor
University of Florida
Target Recruit Count
12
Registration Number
NCT06254326
Locations
🇺🇸

University of Florida Health Shands Hospital, Gainesville, Florida, United States

Improving KIdney Transplantation With Cellular Therapy Study

Recruiting
Conditions
Kidney Transplant Rejection
Immune Tolerance
Interventions
Other: Tolerance induction
First Posted Date
2024-02-06
Last Posted Date
2024-02-28
Lead Sponsor
Western Sydney Local Health District
Target Recruit Count
60
Registration Number
NCT06243289
Locations
🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

Phase 1
Active, not recruiting
Conditions
Embryonal Tumor With Multilayered Rosettes
Medulloblastoma, Childhood
Embryonal Tumor of CNS
Atypical Teratoid/Rhabdoid Tumor of CNS
Pineoblastoma
Interventions
Biological: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)
First Posted Date
2024-01-05
Last Posted Date
2024-06-18
Lead Sponsor
Children's National Research Institute
Target Recruit Count
12
Registration Number
NCT06193759
Locations
🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

First Posted Date
2024-01-05
Last Posted Date
2025-01-07
Lead Sponsor
Genmab
Target Recruit Count
1080
Registration Number
NCT06191744
Locations
🇺🇸

Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 259814, Chicago, Illinois, United States

🇺🇸

Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States

🇺🇸

Christiana Care Health Service /ID# 261207, Newark, Delaware, United States

and more 193 locations

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 3
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2023-12-06
Last Posted Date
2024-11-04
Lead Sponsor
AbbVie
Target Recruit Count
380
Registration Number
NCT06158841
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China

🇺🇸

Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States

🇺🇸

Providence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States

and more 80 locations

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Phase 3
Recruiting
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Interventions
First Posted Date
2023-11-18
Last Posted Date
2025-01-08
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1200
Registration Number
NCT06136559
Locations
🇵🇹

Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3103), Lisbon, Lisboa, Portugal

🇹🇷

Ege Universitesi Hastanesi ( Site 1404), İzmir, Turkey

🇺🇸

USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama, United States

and more 152 locations
© Copyright 2025. All Rights Reserved by MedPath